Amidst recent trading sessions, Krystal Biotech Inc (Symbol: KRYS) has soared past the average analyst 12-month target price of $180.30, settling at $180.42/share. When a stock hits the target set by analysts, it prompts a crucial crossroads for these experts. They can either adjust their target upwards in response to positive fundamental business developments dictating the stock’s surge, or they may consider downgrading it based on valuation concerns.
Within the Zacks coverage universe, there exist 10 distinct analyst targets contributing to the calculated average for Krystal Biotech Inc. However, this average is merely a statistical figure. Below this calculated midpoint, some analysts have set lower targets, with one aiming for $153.00. Conversely, at the opposite end of the spectrum, a single analyst has set an ambitious target of $208.00. The standard deviation stands at $20.116.
The essence of scrutinizing the average price target for KRYS revolves around the concept of the “wisdom of crowds.” It amalgamates the input from various individuals rather than relying solely on the forecast of a single expert. With KRYS surpassing the average target price of $180.30/share, investors now face an opportune moment to reassess the company’s standing. They must weigh whether $180.30 is merely a stepping stone towards an even loftier target, or if the valuation has become overstretched, signaling a prudent moment to consider profit-taking.
| Current KRYS Analyst Ratings Overview | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Months Ago | 3 Months Ago |
| Strong buy ratings: | 11 | 11 | 11 | 11 |
| Buy ratings: | 0 | 0 | 0 | 0 |
| Hold ratings: | 0 | 0 | 0 | 0 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 1.0 | 1.0 | 1.0 | 1.0 |
The average rating depicted in the last row of the table ranges from 1 to 5, with 1 implying a Strong Buy and 5 indicating a Strong Sell. This report has been compiled utilizing data from Zacks Investment Research via Quandl.com, providing investors with valuable insights into the dynamics of KRYS.
Don’t miss out on the top 25 Broker Analyst Picks of the S&P 500 »
For further insights, check out:
• CMAX shares outstanding history
• ANSS Historical Stock Prices
• JAGX Year-To-Date Return
The opinions articulated in this article belong to the author and do not necessarily mirror the views of Nasdaq, Inc.
